title: Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor-Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation (FACE) Trial.
abstract: Purpose The Letrozole (Femara) Versus Anastrozole Clinical Evaluation (FACE) study compared the efficacy and safety of adjuvant letrozole versus anastrozole in postmenopausal patients with hormone receptor (HR) -positive and node-positive early breast cancer (eBC). Methods Postmenopausal women with HR-positive and node-positive eBC were randomly assigned to receive adjuvant therapy with either letrozole (2.5 mg) or anastrozole (1 mg) once per day for 5 years or until recurrence of disease. Patients were stratified on the basis of the number of lymph nodes and human epidermal growth factor receptor 2 status. The primary end point was 5-year disease-free survival (DFS), and the key secondary end points were overall survival and safety. Results A total of 4,136 patients were randomly assigned to receive either letrozole (n = 2,061) or anastrozole (n = 2,075). The final analysis was done at 709 DFS events (letrozole, 341 [16.5%]; anastrozole, 368 [17.7%]). The 5-year estimated DFS rate was 84.9% for letrozole versus 82.9% for anastrozole arm (hazard ratio, 0.93; 95% CI, 0.80 to 1.07; P = .3150). Exploratory analysis showed similar DFS with letrozole and anastrozole in all evaluated subgroups. The 5-year estimated overall survival rate was 89.9% for letrozole versus 89.2% for anastrozole arm (hazard ratio, 0.98; 95% CI, 0.82 to 1.17; P = .7916). Most common grade 3 to 4 adverse events (> 5% of patients) reported for letrozole versus anastrozole were arthralgia (3.9% v 3.3%, and 48.2% v 47.9% for all adverse events), hypertension (1.2% v 1.0%), hot flushes (0.8% v 0.4%), myalgia (0.8% v 0.7%), dyspnea (0.8% v 0.5%), and depression (0.8% v 0.6%). Conclusion Letrozole did not demonstrate significantly superior efficacy or safety compared with anastrozole in postmenopausal patients with HR-positive, node-positive eBC.
authors.affiliation: Ian Smith and Mitch Dowsett, Royal Marsden Hospital; Institute of Cancer Research, London, United Kingdom; Denise Yardley and Howard Burris, Sarah Cannon Research Institute; Tennessee Oncology, Nashville, TN; Richard De Boer, Royal Melbourne and Western Hospitals, Melbourne, Australia; Dino Amadori, Istituto Scientifico Romagnolo per lo Studio e la Cura del Tumori Istituto di Ricovero eCura a Carattere Scientifico, Meldola; Lisa Comarella, CROS NT, Verona, Italy; Kristi McIntyre and Joyce O'Shaughnessy, Texas Oncology, US Oncology; Joyce O'Shaughnessy, Baylor University Medical Center; Baylor Charles A. Sammons Cancer Center; The US Oncology Network, Dallas, TX; Bent Ejlertsen, Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark; Michael Gnant, Medical University of Vienna, Vienna, Austria; Walter Jonat, Universitätsklinikum Schleswig-Holstein, Kiel, Germany; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada; Lowell Hart, Florida Cancer Specialists, Fort Myers, FL; Susan Poggio and Barbara Wamil, Novartis Pharmaceuticals Corporation, East Hanover, NJ; and Herve Salomon, Novartis Pharma, Rueil-Malmaison, France.
authors.forename: Ian
authors.initials: I
authors.lastname: Smith
authors.affiliation: Ian Smith and Mitch Dowsett, Royal Marsden Hospital; Institute of Cancer Research, London, United Kingdom; Denise Yardley and Howard Burris, Sarah Cannon Research Institute; Tennessee Oncology, Nashville, TN; Richard De Boer, Royal Melbourne and Western Hospitals, Melbourne, Australia; Dino Amadori, Istituto Scientifico Romagnolo per lo Studio e la Cura del Tumori Istituto di Ricovero eCura a Carattere Scientifico, Meldola; Lisa Comarella, CROS NT, Verona, Italy; Kristi McIntyre and Joyce O'Shaughnessy, Texas Oncology, US Oncology; Joyce O'Shaughnessy, Baylor University Medical Center; Baylor Charles A. Sammons Cancer Center; The US Oncology Network, Dallas, TX; Bent Ejlertsen, Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark; Michael Gnant, Medical University of Vienna, Vienna, Austria; Walter Jonat, Universitätsklinikum Schleswig-Holstein, Kiel, Germany; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada; Lowell Hart, Florida Cancer Specialists, Fort Myers, FL; Susan Poggio and Barbara Wamil, Novartis Pharmaceuticals Corporation, East Hanover, NJ; and Herve Salomon, Novartis Pharma, Rueil-Malmaison, France.
authors.forename: Denise
authors.initials: D
authors.lastname: Yardley
authors.affiliation: Ian Smith and Mitch Dowsett, Royal Marsden Hospital; Institute of Cancer Research, London, United Kingdom; Denise Yardley and Howard Burris, Sarah Cannon Research Institute; Tennessee Oncology, Nashville, TN; Richard De Boer, Royal Melbourne and Western Hospitals, Melbourne, Australia; Dino Amadori, Istituto Scientifico Romagnolo per lo Studio e la Cura del Tumori Istituto di Ricovero eCura a Carattere Scientifico, Meldola; Lisa Comarella, CROS NT, Verona, Italy; Kristi McIntyre and Joyce O'Shaughnessy, Texas Oncology, US Oncology; Joyce O'Shaughnessy, Baylor University Medical Center; Baylor Charles A. Sammons Cancer Center; The US Oncology Network, Dallas, TX; Bent Ejlertsen, Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark; Michael Gnant, Medical University of Vienna, Vienna, Austria; Walter Jonat, Universitätsklinikum Schleswig-Holstein, Kiel, Germany; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada; Lowell Hart, Florida Cancer Specialists, Fort Myers, FL; Susan Poggio and Barbara Wamil, Novartis Pharmaceuticals Corporation, East Hanover, NJ; and Herve Salomon, Novartis Pharma, Rueil-Malmaison, France.
authors.forename: Howard
authors.initials: H
authors.lastname: Burris
authors.affiliation: Ian Smith and Mitch Dowsett, Royal Marsden Hospital; Institute of Cancer Research, London, United Kingdom; Denise Yardley and Howard Burris, Sarah Cannon Research Institute; Tennessee Oncology, Nashville, TN; Richard De Boer, Royal Melbourne and Western Hospitals, Melbourne, Australia; Dino Amadori, Istituto Scientifico Romagnolo per lo Studio e la Cura del Tumori Istituto di Ricovero eCura a Carattere Scientifico, Meldola; Lisa Comarella, CROS NT, Verona, Italy; Kristi McIntyre and Joyce O'Shaughnessy, Texas Oncology, US Oncology; Joyce O'Shaughnessy, Baylor University Medical Center; Baylor Charles A. Sammons Cancer Center; The US Oncology Network, Dallas, TX; Bent Ejlertsen, Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark; Michael Gnant, Medical University of Vienna, Vienna, Austria; Walter Jonat, Universitätsklinikum Schleswig-Holstein, Kiel, Germany; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada; Lowell Hart, Florida Cancer Specialists, Fort Myers, FL; Susan Poggio and Barbara Wamil, Novartis Pharmaceuticals Corporation, East Hanover, NJ; and Herve Salomon, Novartis Pharma, Rueil-Malmaison, France.
authors.forename: Richard
authors.initials: R
authors.lastname: De Boer
authors.affiliation: Ian Smith and Mitch Dowsett, Royal Marsden Hospital; Institute of Cancer Research, London, United Kingdom; Denise Yardley and Howard Burris, Sarah Cannon Research Institute; Tennessee Oncology, Nashville, TN; Richard De Boer, Royal Melbourne and Western Hospitals, Melbourne, Australia; Dino Amadori, Istituto Scientifico Romagnolo per lo Studio e la Cura del Tumori Istituto di Ricovero eCura a Carattere Scientifico, Meldola; Lisa Comarella, CROS NT, Verona, Italy; Kristi McIntyre and Joyce O'Shaughnessy, Texas Oncology, US Oncology; Joyce O'Shaughnessy, Baylor University Medical Center; Baylor Charles A. Sammons Cancer Center; The US Oncology Network, Dallas, TX; Bent Ejlertsen, Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark; Michael Gnant, Medical University of Vienna, Vienna, Austria; Walter Jonat, Universitätsklinikum Schleswig-Holstein, Kiel, Germany; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada; Lowell Hart, Florida Cancer Specialists, Fort Myers, FL; Susan Poggio and Barbara Wamil, Novartis Pharmaceuticals Corporation, East Hanover, NJ; and Herve Salomon, Novartis Pharma, Rueil-Malmaison, France.
authors.forename: Dino
authors.initials: D
authors.lastname: Amadori
authors.affiliation: Ian Smith and Mitch Dowsett, Royal Marsden Hospital; Institute of Cancer Research, London, United Kingdom; Denise Yardley and Howard Burris, Sarah Cannon Research Institute; Tennessee Oncology, Nashville, TN; Richard De Boer, Royal Melbourne and Western Hospitals, Melbourne, Australia; Dino Amadori, Istituto Scientifico Romagnolo per lo Studio e la Cura del Tumori Istituto di Ricovero eCura a Carattere Scientifico, Meldola; Lisa Comarella, CROS NT, Verona, Italy; Kristi McIntyre and Joyce O'Shaughnessy, Texas Oncology, US Oncology; Joyce O'Shaughnessy, Baylor University Medical Center; Baylor Charles A. Sammons Cancer Center; The US Oncology Network, Dallas, TX; Bent Ejlertsen, Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark; Michael Gnant, Medical University of Vienna, Vienna, Austria; Walter Jonat, Universitätsklinikum Schleswig-Holstein, Kiel, Germany; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada; Lowell Hart, Florida Cancer Specialists, Fort Myers, FL; Susan Poggio and Barbara Wamil, Novartis Pharmaceuticals Corporation, East Hanover, NJ; and Herve Salomon, Novartis Pharma, Rueil-Malmaison, France.
authors.forename: Kristi
authors.initials: K
authors.lastname: McIntyre
authors.affiliation: Ian Smith and Mitch Dowsett, Royal Marsden Hospital; Institute of Cancer Research, London, United Kingdom; Denise Yardley and Howard Burris, Sarah Cannon Research Institute; Tennessee Oncology, Nashville, TN; Richard De Boer, Royal Melbourne and Western Hospitals, Melbourne, Australia; Dino Amadori, Istituto Scientifico Romagnolo per lo Studio e la Cura del Tumori Istituto di Ricovero eCura a Carattere Scientifico, Meldola; Lisa Comarella, CROS NT, Verona, Italy; Kristi McIntyre and Joyce O'Shaughnessy, Texas Oncology, US Oncology; Joyce O'Shaughnessy, Baylor University Medical Center; Baylor Charles A. Sammons Cancer Center; The US Oncology Network, Dallas, TX; Bent Ejlertsen, Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark; Michael Gnant, Medical University of Vienna, Vienna, Austria; Walter Jonat, Universitätsklinikum Schleswig-Holstein, Kiel, Germany; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada; Lowell Hart, Florida Cancer Specialists, Fort Myers, FL; Susan Poggio and Barbara Wamil, Novartis Pharmaceuticals Corporation, East Hanover, NJ; and Herve Salomon, Novartis Pharma, Rueil-Malmaison, France.
authors.forename: Bent
authors.initials: B
authors.lastname: Ejlertsen
authors.affiliation: Ian Smith and Mitch Dowsett, Royal Marsden Hospital; Institute of Cancer Research, London, United Kingdom; Denise Yardley and Howard Burris, Sarah Cannon Research Institute; Tennessee Oncology, Nashville, TN; Richard De Boer, Royal Melbourne and Western Hospitals, Melbourne, Australia; Dino Amadori, Istituto Scientifico Romagnolo per lo Studio e la Cura del Tumori Istituto di Ricovero eCura a Carattere Scientifico, Meldola; Lisa Comarella, CROS NT, Verona, Italy; Kristi McIntyre and Joyce O'Shaughnessy, Texas Oncology, US Oncology; Joyce O'Shaughnessy, Baylor University Medical Center; Baylor Charles A. Sammons Cancer Center; The US Oncology Network, Dallas, TX; Bent Ejlertsen, Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark; Michael Gnant, Medical University of Vienna, Vienna, Austria; Walter Jonat, Universitätsklinikum Schleswig-Holstein, Kiel, Germany; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada; Lowell Hart, Florida Cancer Specialists, Fort Myers, FL; Susan Poggio and Barbara Wamil, Novartis Pharmaceuticals Corporation, East Hanover, NJ; and Herve Salomon, Novartis Pharma, Rueil-Malmaison, France.
authors.forename: Michael
authors.initials: M
authors.lastname: Gnant
authors.affiliation: Ian Smith and Mitch Dowsett, Royal Marsden Hospital; Institute of Cancer Research, London, United Kingdom; Denise Yardley and Howard Burris, Sarah Cannon Research Institute; Tennessee Oncology, Nashville, TN; Richard De Boer, Royal Melbourne and Western Hospitals, Melbourne, Australia; Dino Amadori, Istituto Scientifico Romagnolo per lo Studio e la Cura del Tumori Istituto di Ricovero eCura a Carattere Scientifico, Meldola; Lisa Comarella, CROS NT, Verona, Italy; Kristi McIntyre and Joyce O'Shaughnessy, Texas Oncology, US Oncology; Joyce O'Shaughnessy, Baylor University Medical Center; Baylor Charles A. Sammons Cancer Center; The US Oncology Network, Dallas, TX; Bent Ejlertsen, Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark; Michael Gnant, Medical University of Vienna, Vienna, Austria; Walter Jonat, Universitätsklinikum Schleswig-Holstein, Kiel, Germany; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada; Lowell Hart, Florida Cancer Specialists, Fort Myers, FL; Susan Poggio and Barbara Wamil, Novartis Pharmaceuticals Corporation, East Hanover, NJ; and Herve Salomon, Novartis Pharma, Rueil-Malmaison, France.
authors.forename: Walter
authors.initials: W
authors.lastname: Jonat
authors.affiliation: Ian Smith and Mitch Dowsett, Royal Marsden Hospital; Institute of Cancer Research, London, United Kingdom; Denise Yardley and Howard Burris, Sarah Cannon Research Institute; Tennessee Oncology, Nashville, TN; Richard De Boer, Royal Melbourne and Western Hospitals, Melbourne, Australia; Dino Amadori, Istituto Scientifico Romagnolo per lo Studio e la Cura del Tumori Istituto di Ricovero eCura a Carattere Scientifico, Meldola; Lisa Comarella, CROS NT, Verona, Italy; Kristi McIntyre and Joyce O'Shaughnessy, Texas Oncology, US Oncology; Joyce O'Shaughnessy, Baylor University Medical Center; Baylor Charles A. Sammons Cancer Center; The US Oncology Network, Dallas, TX; Bent Ejlertsen, Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark; Michael Gnant, Medical University of Vienna, Vienna, Austria; Walter Jonat, Universitätsklinikum Schleswig-Holstein, Kiel, Germany; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada; Lowell Hart, Florida Cancer Specialists, Fort Myers, FL; Susan Poggio and Barbara Wamil, Novartis Pharmaceuticals Corporation, East Hanover, NJ; and Herve Salomon, Novartis Pharma, Rueil-Malmaison, France.
authors.forename: Kathleen I
authors.initials: KI
authors.lastname: Pritchard
authors.affiliation: Ian Smith and Mitch Dowsett, Royal Marsden Hospital; Institute of Cancer Research, London, United Kingdom; Denise Yardley and Howard Burris, Sarah Cannon Research Institute; Tennessee Oncology, Nashville, TN; Richard De Boer, Royal Melbourne and Western Hospitals, Melbourne, Australia; Dino Amadori, Istituto Scientifico Romagnolo per lo Studio e la Cura del Tumori Istituto di Ricovero eCura a Carattere Scientifico, Meldola; Lisa Comarella, CROS NT, Verona, Italy; Kristi McIntyre and Joyce O'Shaughnessy, Texas Oncology, US Oncology; Joyce O'Shaughnessy, Baylor University Medical Center; Baylor Charles A. Sammons Cancer Center; The US Oncology Network, Dallas, TX; Bent Ejlertsen, Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark; Michael Gnant, Medical University of Vienna, Vienna, Austria; Walter Jonat, Universitätsklinikum Schleswig-Holstein, Kiel, Germany; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada; Lowell Hart, Florida Cancer Specialists, Fort Myers, FL; Susan Poggio and Barbara Wamil, Novartis Pharmaceuticals Corporation, East Hanover, NJ; and Herve Salomon, Novartis Pharma, Rueil-Malmaison, France.
authors.forename: Mitch
authors.initials: M
authors.lastname: Dowsett
authors.affiliation: Ian Smith and Mitch Dowsett, Royal Marsden Hospital; Institute of Cancer Research, London, United Kingdom; Denise Yardley and Howard Burris, Sarah Cannon Research Institute; Tennessee Oncology, Nashville, TN; Richard De Boer, Royal Melbourne and Western Hospitals, Melbourne, Australia; Dino Amadori, Istituto Scientifico Romagnolo per lo Studio e la Cura del Tumori Istituto di Ricovero eCura a Carattere Scientifico, Meldola; Lisa Comarella, CROS NT, Verona, Italy; Kristi McIntyre and Joyce O'Shaughnessy, Texas Oncology, US Oncology; Joyce O'Shaughnessy, Baylor University Medical Center; Baylor Charles A. Sammons Cancer Center; The US Oncology Network, Dallas, TX; Bent Ejlertsen, Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark; Michael Gnant, Medical University of Vienna, Vienna, Austria; Walter Jonat, Universitätsklinikum Schleswig-Holstein, Kiel, Germany; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada; Lowell Hart, Florida Cancer Specialists, Fort Myers, FL; Susan Poggio and Barbara Wamil, Novartis Pharmaceuticals Corporation, East Hanover, NJ; and Herve Salomon, Novartis Pharma, Rueil-Malmaison, France.
authors.forename: Lowell
authors.initials: L
authors.lastname: Hart
authors.affiliation: Ian Smith and Mitch Dowsett, Royal Marsden Hospital; Institute of Cancer Research, London, United Kingdom; Denise Yardley and Howard Burris, Sarah Cannon Research Institute; Tennessee Oncology, Nashville, TN; Richard De Boer, Royal Melbourne and Western Hospitals, Melbourne, Australia; Dino Amadori, Istituto Scientifico Romagnolo per lo Studio e la Cura del Tumori Istituto di Ricovero eCura a Carattere Scientifico, Meldola; Lisa Comarella, CROS NT, Verona, Italy; Kristi McIntyre and Joyce O'Shaughnessy, Texas Oncology, US Oncology; Joyce O'Shaughnessy, Baylor University Medical Center; Baylor Charles A. Sammons Cancer Center; The US Oncology Network, Dallas, TX; Bent Ejlertsen, Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark; Michael Gnant, Medical University of Vienna, Vienna, Austria; Walter Jonat, Universitätsklinikum Schleswig-Holstein, Kiel, Germany; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada; Lowell Hart, Florida Cancer Specialists, Fort Myers, FL; Susan Poggio and Barbara Wamil, Novartis Pharmaceuticals Corporation, East Hanover, NJ; and Herve Salomon, Novartis Pharma, Rueil-Malmaison, France.
authors.forename: Susan
authors.initials: S
authors.lastname: Poggio
authors.affiliation: Ian Smith and Mitch Dowsett, Royal Marsden Hospital; Institute of Cancer Research, London, United Kingdom; Denise Yardley and Howard Burris, Sarah Cannon Research Institute; Tennessee Oncology, Nashville, TN; Richard De Boer, Royal Melbourne and Western Hospitals, Melbourne, Australia; Dino Amadori, Istituto Scientifico Romagnolo per lo Studio e la Cura del Tumori Istituto di Ricovero eCura a Carattere Scientifico, Meldola; Lisa Comarella, CROS NT, Verona, Italy; Kristi McIntyre and Joyce O'Shaughnessy, Texas Oncology, US Oncology; Joyce O'Shaughnessy, Baylor University Medical Center; Baylor Charles A. Sammons Cancer Center; The US Oncology Network, Dallas, TX; Bent Ejlertsen, Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark; Michael Gnant, Medical University of Vienna, Vienna, Austria; Walter Jonat, Universitätsklinikum Schleswig-Holstein, Kiel, Germany; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada; Lowell Hart, Florida Cancer Specialists, Fort Myers, FL; Susan Poggio and Barbara Wamil, Novartis Pharmaceuticals Corporation, East Hanover, NJ; and Herve Salomon, Novartis Pharma, Rueil-Malmaison, France.
authors.forename: Lisa
authors.initials: L
authors.lastname: Comarella
authors.affiliation: Ian Smith and Mitch Dowsett, Royal Marsden Hospital; Institute of Cancer Research, London, United Kingdom; Denise Yardley and Howard Burris, Sarah Cannon Research Institute; Tennessee Oncology, Nashville, TN; Richard De Boer, Royal Melbourne and Western Hospitals, Melbourne, Australia; Dino Amadori, Istituto Scientifico Romagnolo per lo Studio e la Cura del Tumori Istituto di Ricovero eCura a Carattere Scientifico, Meldola; Lisa Comarella, CROS NT, Verona, Italy; Kristi McIntyre and Joyce O'Shaughnessy, Texas Oncology, US Oncology; Joyce O'Shaughnessy, Baylor University Medical Center; Baylor Charles A. Sammons Cancer Center; The US Oncology Network, Dallas, TX; Bent Ejlertsen, Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark; Michael Gnant, Medical University of Vienna, Vienna, Austria; Walter Jonat, Universitätsklinikum Schleswig-Holstein, Kiel, Germany; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada; Lowell Hart, Florida Cancer Specialists, Fort Myers, FL; Susan Poggio and Barbara Wamil, Novartis Pharmaceuticals Corporation, East Hanover, NJ; and Herve Salomon, Novartis Pharma, Rueil-Malmaison, France.
authors.forename: Herve
authors.initials: H
authors.lastname: Salomon
authors.affiliation: Ian Smith and Mitch Dowsett, Royal Marsden Hospital; Institute of Cancer Research, London, United Kingdom; Denise Yardley and Howard Burris, Sarah Cannon Research Institute; Tennessee Oncology, Nashville, TN; Richard De Boer, Royal Melbourne and Western Hospitals, Melbourne, Australia; Dino Amadori, Istituto Scientifico Romagnolo per lo Studio e la Cura del Tumori Istituto di Ricovero eCura a Carattere Scientifico, Meldola; Lisa Comarella, CROS NT, Verona, Italy; Kristi McIntyre and Joyce O'Shaughnessy, Texas Oncology, US Oncology; Joyce O'Shaughnessy, Baylor University Medical Center; Baylor Charles A. Sammons Cancer Center; The US Oncology Network, Dallas, TX; Bent Ejlertsen, Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark; Michael Gnant, Medical University of Vienna, Vienna, Austria; Walter Jonat, Universitätsklinikum Schleswig-Holstein, Kiel, Germany; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada; Lowell Hart, Florida Cancer Specialists, Fort Myers, FL; Susan Poggio and Barbara Wamil, Novartis Pharmaceuticals Corporation, East Hanover, NJ; and Herve Salomon, Novartis Pharma, Rueil-Malmaison, France.
authors.forename: Barbara
authors.initials: B
authors.lastname: Wamil
authors.affiliation: Ian Smith and Mitch Dowsett, Royal Marsden Hospital; Institute of Cancer Research, London, United Kingdom; Denise Yardley and Howard Burris, Sarah Cannon Research Institute; Tennessee Oncology, Nashville, TN; Richard De Boer, Royal Melbourne and Western Hospitals, Melbourne, Australia; Dino Amadori, Istituto Scientifico Romagnolo per lo Studio e la Cura del Tumori Istituto di Ricovero eCura a Carattere Scientifico, Meldola; Lisa Comarella, CROS NT, Verona, Italy; Kristi McIntyre and Joyce O'Shaughnessy, Texas Oncology, US Oncology; Joyce O'Shaughnessy, Baylor University Medical Center; Baylor Charles A. Sammons Cancer Center; The US Oncology Network, Dallas, TX; Bent Ejlertsen, Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark; Michael Gnant, Medical University of Vienna, Vienna, Austria; Walter Jonat, Universitätsklinikum Schleswig-Holstein, Kiel, Germany; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada; Lowell Hart, Florida Cancer Specialists, Fort Myers, FL; Susan Poggio and Barbara Wamil, Novartis Pharmaceuticals Corporation, East Hanover, NJ; and Herve Salomon, Novartis Pharma, Rueil-Malmaison, France.
authors.forename: Joyce
authors.initials: J
authors.lastname: O'Shaughnessy
mesh_terms: D000368:Aged; D000077384:Anastrozole; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects / Q000627:therapeutic use*; D018771:Arthralgia / Q000139:chemically induced; D001943:Breast Neoplasms / Q000473:pathology / Q000628:therapy*; D017024:Chemotherapy, Adjuvant; D003863:Depression / Q000139:chemically induced; D018572:Disease-Free Survival; D004417:Dyspnea / Q000139:chemically induced; D005260:Female; D019584:Hot Flashes / Q000139:chemically induced; D006801:Humans; D006973:Hypertension / Q000139:chemically induced; D000077289:Letrozole; D008207:Lymphatic Metastasis; D008408:Mastectomy; D008875:Middle Aged; D063806:Myalgia / Q000139:chemically induced; D009367:Neoplasm Staging; D009570:Nitriles / Q000009:adverse effects / Q000627:therapeutic use*; D017698:Postmenopause; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis; D011960:Receptors, Estrogen / Q000032:analysis; D011980:Receptors, Progesterone / Q000032:analysis; D015996:Survival Rate; D014230:Triazoles / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000077384:Anastrozole; D018931:Antineoplastic Agents, Hormonal; D000077289:Letrozole; D009570:Nitriles; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D014230:Triazoles; C508053:ERBB2 protein, human